非靶向代谢组学为肌肉减少症的发病机制提供了新的见解。在这项研究中，我们通过基于 LC-MS 的非靶向代谢组学进行队列研究，探讨了与肌肉减少症风险升高相关的血浆代谢特征。在这项来自成人体能和健康队列研究 (APFHCS) 的嵌套病例对照研究中，我们研究人员从 30 名新发肌少症受试者（平均年龄 73.2 ± 5.6 岁）和 30 名健康对照者（平均年龄 74.2 ± 4.6 岁）中收集了血浆样本，这些样本与年龄、性别、BMI、生活方式和合并症相匹配。采用非靶向代谢组学方法来辨别新诊断肌肉减少症个体中存在的代谢组谱变化。在将新发肌肉减少症患者与正常对照进行比较时，使用液相色谱-质谱法 (LC-MS) 进行的综合分析确定了总共62 种代谢物，主要包括脂质、类脂分子、有机酸和衍生物。受试者工作特征（ROC）曲线分析表明，3个代谢物次黄嘌呤（AUC=0.819，95% CI=0.711-0.927）、L-2-氨基-3-氧代丁酸（AUC=0.733，95% CI=0.598-0.868） ) 和 PC(14:0/20:2(11Z,14Z)) (AUC= 0.717, 95% CI=0.587-0.846) 曲线下面积最高。然后，观察到这些重要的代谢物在四种不同的代谢途径中显着富集，即“嘌呤代谢”； “甲状旁腺激素的合成、分泌和作用”； “癌症中的胆碱代谢”；目前的研究阐明了在诊断为肌肉减少症的个体中观察到的代谢紊乱。所鉴定的代谢物有望成为潜在的生物标志物，为探索与肌肉减少症相关的潜在病理机制提供途径。版权所有 © 2024 Han、Chen、Liang、Liu、Yu、Song、Zhao、Zhang、Zhu、Shi 和Guo。

Untargeted metabonomics has provided new insight into the pathogenesis of sarcopenia. In this study, we explored plasma metabolic signatures linked to a heightened risk of sarcopenia in a cohort study by LC-MS-based untargeted metabonomics.In this nested case-control study from the Adult Physical Fitness and Health Cohort Study (APFHCS), we collected blood plasma samples from 30 new-onset sarcopenia subjects (mean age 73.2 ± 5.6 years) and 30 healthy controls (mean age 74.2 ± 4.6 years) matched by age, sex, BMI, lifestyle, and comorbidities. An untargeted metabolomics methodology was employed to discern the metabolomic profile alterations present in individuals exhibiting newly diagnosed sarcopenia.In comparing individuals with new-onset sarcopenia to normal controls, a comprehensive analysis using liquid chromatography-mass spectrometry (LC-MS) identified a total of 62 metabolites, predominantly comprising lipids, lipid-like molecules, organic acids, and derivatives. Receiver operating characteristic (ROC) curve analysis indicated that the three metabolites hypoxanthine (AUC=0.819, 95% CI=0.711-0.927), L-2-amino-3-oxobutanoic acid (AUC=0.733, 95% CI=0.598-0.868) and PC(14:0/20:2(11Z,14Z)) (AUC= 0.717, 95% CI=0.587-0.846) had the highest areas under the curve. Then, these significant metabolites were observed to be notably enriched in four distinct metabolic pathways, namely, "purine metabolism"; "parathyroid hormone synthesis, secretion and action"; "choline metabolism in cancer"; and "tuberculosis".The current investigation elucidates the metabolic perturbations observed in individuals diagnosed with sarcopenia. The identified metabolites hold promise as potential biomarkers, offering avenues for exploring the underlying pathological mechanisms associated with sarcopenia.Copyright © 2024 Han, Chen, Liang, Liu, Yu, Song, Zhao, Zhang, Zhu, Shi and Guo.